Literature DB >> 12486498

Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells.

L Polastri1, F Galbiati, F Bertuzzi, P Fiorina, R Nano, S Gregori, L Aldrighetti, G Pozza, A Secchi, L Adorini, A M Davalli.   

Abstract

Despite the considerable interest for islet and pancreas transplantation, remarkably little is known about the direct effects of immunosuppressive drugs on human beta-cell function. We measured different insulin secretory parameters and insulin gene expression of human islets cultured for 5 days in the presence of mycophenolate mofetil (MMF), cyclosporin A (CsA), tacrolimus (FK506) or a mixture of 3 cytokines. Basal insulin release after exposure to cytokines and FK506 was significantly higher than in control islets. Responsiveness to an acute glucose stimulus did not differ significantly between control and treated islets. However, absolute incremental insulin responses (delta-AUCs) of islets exposed to cytokines or FK506 were significantly higher compared to islets exposed to CsA or MMF, mainly because of the higher basal release. Indeed, maximal over basal release (stimulation index, SI) tended to be lower in islets exposed to FK506 than in control islets. Insulin gene expression was significantly reduced only in islets exposed to CsA. FK506 was, among those tested, the immunosuppressive drug that most profoundly altered the normal insulin secretory pattern of human beta-cells, whereas CsA was the only inhibiting insulin gene expression. Although the abnormalities induced by the immunosoppressive drugs utilized in this study were modest, these in vitro data are consistent with the reported in vivo diabetogenicity of CsA and FK506 and point to MMF as the ideal immunosuppressive agent from a pancreatic beta-cell point of view.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486498     DOI: 10.1007/s005920200039

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  20 in total

Review 1.  CMV prophylaxis: a useful step towards prevention of post-transplant diabetes?

Authors:  R M Smith
Journal:  Diabetologia       Date:  2004-08-25       Impact factor: 10.122

2.  Autocrine insulin action activates Akt and increases survival of isolated human islets.

Authors:  R Aikin; S Hanley; D Maysinger; M Lipsett; M Castellarin; S Paraskevas; L Rosenberg
Journal:  Diabetologia       Date:  2006-10-20       Impact factor: 10.122

3.  The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro.

Authors:  H Scholz; T Lund; M K Dahle; J L Collins; O Korsgren; J E Wang; A Foss
Journal:  Diabetologia       Date:  2009-05-05       Impact factor: 10.122

4.  The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells.

Authors:  C T Bussiere; J R T Lakey; A M J Shapiro; G S Korbutt
Journal:  Diabetologia       Date:  2006-08-09       Impact factor: 10.122

Review 5.  Pharmacogenetics of posttransplant diabetes mellitus.

Authors:  P Lancia; T Adam de Beaumais; E Jacqz-Aigrain
Journal:  Pharmacogenomics J       Date:  2017-03-28       Impact factor: 3.550

Review 6.  Genetically modified mesenchymal stem cells for improved islet transplantation.

Authors:  Hao Wu; Zhaoyang Ye; Ram I Mahato
Journal:  Mol Pharm       Date:  2011-07-07       Impact factor: 4.939

Review 7.  Risk factors for new-onset diabetes after kidney transplantation.

Authors:  Adnan Sharif; Keshwar Baboolal
Journal:  Nat Rev Nephrol       Date:  2010-05-25       Impact factor: 28.314

8.  Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells.

Authors:  L A Øzbay; K Smidt; D M Mortensen; J Carstens; K A Jørgensen; J Rungby
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

Review 9.  Glucose metabolism after pancreas-kidney transplantation.

Authors:  Elizabeth Diakoff
Journal:  Curr Diab Rep       Date:  2008-08       Impact factor: 4.810

10.  Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells.

Authors:  Lars G Grunnet; Reid Aikin; Morten F Tonnesen; Steven Paraskevas; Lykke Blaabjerg; Joachim Størling; Lawrence Rosenberg; Nils Billestrup; Dusica Maysinger; Thomas Mandrup-Poulsen
Journal:  Diabetes       Date:  2009-05-26       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.